# Pizarra — PT-pseudo_033f1a8e1503 (task 1)

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_033f1a8e1503
Task: 1

Encounter: Urology - outpatient on 12 Jan 2025.
Referrer: Dr. C. Peters (GP).
Type: Follow-up - PSA + MRI.

Clinical data (read-only — values loaded from the record):
  - 60-year-old male
  - PSA: 5.9 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.199 ng/mL²
  - PSA velocity: 1.83 ng/mL/yr
  - Prior PSA: 4.1 ng/mL
  - Prostate volume: 29.71 mL
  - Months since last PSA: 1
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: None (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.84285355 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Hypertension, Coronary artery disease, Benign prostatic hyperplasia
  - Problem list / PMHx: Hypertension, Coronary artery disease, Benign prostatic hyperplasia
  - Current medication: amlodipine, aspirin 80 mg, atorvastatin, metoprolol, tamsulosin
  - Allergies: NKA
  - Additional notes: PSA 5.9 ng/mL. PI-RADS 5. PSAD 0.20. Prostate volume 30 mL. csPCa 0.84.

Vitals: weight 82 kg, height 184 cm, BMI 24.2, BP 113/77 mmHg, HR 77 bpm. Smoking: Ex-smoker (31 pack-yr, quit 2022).

Chief complaint: Routine monitoring after mpMRI completion and detection of an upward PSA trajectory.

History: A 60-year-old retired carpenter who has never married and currently resides with his partner has remained under routine observation since an initial PSA elevation was flagged in April 2022. He walks twenty minutes daily and ceased tobacco use completely in 2022, concluding a thirty-one pack-year smoking history. His pharmacological profile consists of amlodipine, metoprolol, aspirin 80 mg, atorvastatin, and tamsulosin, the latter addressing benign prostatic hyperplasia that yields minor bothersome symptoms (IPSS 7/35). Underlying hypertension and coronary artery disease remain stable. No prior biopsy history has been recorded. Recent outpatient visits covered audiological screening, pulmonary function tests for established COPD, and dermatological evaluation for actinic keratosis. A cholecystectomy performed during his forties represents his only surgical history. He reports no acute complaints or systemic symptoms beyond these managed chronic conditions.

Physical examination: DRE reveals a uniformly smooth prostatic contour, free of nodularity or asymmetrical firmness. Systemic assessment shows no acute abnormalities, with cardiovascular and pulmonary signs aligning with his established medical background.

Patient info: retired carpenter; Never married; Lives with partner.
Next of kin: Spouse / partner (primary contact).

Lifestyle: alcohol 3 units / week; exercise Walking 20 min/day; IPSS score: 7/35 (mild LUTS).

Recent other appointments: Dermatology — actinic keratosis check; Pulmonary function test — known COPD follow-up; Audiology — hearing test.
Admin: Hard of hearing — speak clearly; prefers written summaries.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents actually exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status shown in the panel above is all the pathology information on record.]

## [2] INITIAL RECOMMENDATION (statistical prior)

**EXPERT-PRIOR** — *statistical expert; k-NN over 8 structured variables of THIS prompt only, trained on 91 labelled cases, leave-one-out honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: BIOPSY
  p(biopsy = yes) = 0.75 +/- 0.18   (95% CI 0.34-0.98)

Where the uncertainty comes from:
  - aleatoric  dA = 0.15  (the nearest labelled cases disagree with each other)
  - epistemic  dA = 0.10  (few labelled cases resemble this one)
  - 5.6 effective neighbours out of 10; 4 of the 5 closest labelled cases were biopsied
  - 80%-coverage conformal set: {yes}

TIER 'supports': A +/- dA does not cross 0.5, but A +/- 1.96*dA does. There is a direction, not a conclusion. Measured accuracy in this tier: 0.67. Treat it as a weighted vote, not as a decision.

Variables it actually read (from the visible panel only, no documents retrieved):
  pirads=5.0, bx_ord=0.0, psa=5.9, age=60.0, psad=0.199, dre_ord=0.0, vol=29.71, n_pmhx=3.0
  missing / not evaluable: none

Out-of-fold performance of this recommender on the 91 labelled cases (5x5 CV):
  accuracy 0.703, balanced accuracy 0.662, AUC 0.75, ECE 0.095.
It is right about 7 times out of 10 overall. It is NOT an oracle and it has never seen the
radiology report, the PSA trajectory, the laboratory panel or the previous notes.

## [3] GUIDELINE CRITERION FOR THIS SITUATION

**EXPERT-PROTOCOL** — *protocol expert; applies the guideline criterion for this patient's clinical situation*

CLINICAL SITUATION: biopsy-naive.

CRITERION VERDICT: BIOPSY.

The criterion: Biopsy when the mpMRI shows a PI-RADS 3 or higher lesion; defer when PI-RADS is 1-2.

In the labelled cohort this criterion matched the reading urologist in every one of the 24 biopsy-naive cases (20 of them PI-RADS 4-5 and biopsied, 4 of them PI-RADS 2 or unreadable and deferred).

Track record of this criterion on the labelled cohort: 24 of 24 cases matched the reading urologist. Departing from it needs a specific finding from a retrieved document, named explicitly - not a restatement of the panel numbers it already used.

Like the statistical prior, this expert has read ONLY the visible panel. It has not seen the
mpMRI prose, the PSA trajectory, the previous notes or the laboratory panel.

## [4] GAPS AND DOUBTS

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
The statistical prior only used the visible panel data (PI-RADS=5.0, PSA=5.9, PSA density=0.199, Age=60.0, DRE=Normal, Volume=29.71, N_pmhx=3.0). It failed to incorporate the PSA velocity (1.83 ng/mL/yr), the specific context of the PI-RADS 5 score relative to the PSA density threshold (0.20 ng/mL²), and the specific guidance regarding biopsy-naive status.

WHY THE SUGGESTION COULD BE WRONG
The prior suggested biopsy based on a high probability (0.75), but the guideline criterion is based on PI-RADS $\ge 3$, which is met. However, the guideline also suggests omitting biopsy if PSA density is $< 0.10 \text{ ng/mL/cc}$ and no family history is present, which this patient's PSA density (0.199) is close to the threshold, and the prior did not weigh this specific risk stratification. The prior's high probability might be inflated because it did not account for the specific risk-adapted matrix mentioned in the guidelines.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
radiology report - does the lesion compare with a previous MRI?
laboratory panel - to confirm the PSA density value and check for other relevant lab markers.
previous GP / urology consultation notes - to understand the context of the initial PSA elevation and the trajectory.
laboratory panel - to confirm the PSA density value and check for other relevant lab markers.
family-history of prostate cancer (anamnesis)
These documents could refine the decision by confirming if the PSA density falls into a specific risk category defined by the guidelines.

GUIDELINE ANCHOR
The guideline states that patients with a PI-RADS 3-5 lesion are considered at risk of csPCa and may be candidates for MRI-targeted biopsy. It also notes that omitting biopsy is suggested when MRI is negative (PI-RADS $\le 2$), PSA density $< 0.10 \text{ ng/mL/cc}$, and no family history is present.

## [5] EVIDENCE REPORT

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
get_mri_report
{"case_id": "PT-pseudo_033f1a8e1503", "radiology_report": "PI-RADS 5 lesion in the left peripheral zone. Prostate volume 29.71 mL; PSAD 0.199 ng/mL/mL. csPCa predicted probability 0.84285355."}
get_psa_trend
{"case_id": "PT-pseudo_033f1a8e1503", "psa_trend": [{"date": "Apr 2022", "val": 4.2}, {"date": "Sep 2023", "val": 3.4}, {"date": "Jan 2025", "val": 5.9}]}
get_previous_notes
{"case_id": "PT-pseudo_033f1a8e1503", "previous_notes": [{"date": "18 Jan 2024", "author": "Dr. C. Peters (GP)", "text": "Laboratory results showed a PSA rise to 4.1 ng/mL in September 2023, following a baseline of 2.8 ng/mL in April 2022. Driven by this trend and mild urinary complaints, clinicians ordered an mpMRI and initiated a urology referral. Tamsulosin remained part of the regimen for symptom management."}]}
get_lab_results
{"case_id": "PT-pseudo_033f1a8e1503", "laboratory_results": [{"name": "PSA", "val": "5.9 ng/mL", "date": "10 Dec 2024", "flag": "H"}, {"name": "Free PSA", "val": "0.93 ng/mL", "date": "10 Dec 2024", "flag": ""}, {"name": "%Free PSA", "val": "16%", "date": "10 Dec 2024", "flag": "L"}]}
NOT RETRIEVED
The specific family history anamnesis was not retrieved, which could potentially influence the decision based on guideline criteria.
WHAT THE EVIDENCE SUPPORTS
FOR sampling this patient now:
- mpMRI report: PI-RADS 5 lesion in the left peripheral zone.
- PSA trend: Rising trajectory from 4.2 ng/mL (Apr 2022) to 5.9 ng/mL (Jan 2025).
- Previous notes: Patient was referred for mpMRI due to PSA rise and trajectory.
AGAINST sampling this patient now:
- Lab results: %Free PSA is 16% (which is not explicitly below the 10% threshold mentioned in the LLM-1 analysis).
- Guideline context: The guideline suggests omitting biopsy if PSA density is $< 0.10 \text{ ng/mL/cc}$ and no family history is present.
WHERE THIS LEANS
The evidence strongly supports biopsy due to the PI-RADS 5 score and the rising PSA trajectory, aligning with the expert protocol's criterion.

[Sections actually revealed in this consultation: radiology_report, psa_trend, previous_notes, laboratory_results. Tools executed: get_lab_results, get_mri_report, get_previous_notes, get_psa_trend.]

## [6] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [7] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: clear)

Biopsy is recommended because the mpMRI demonstrated a PI-RADS 5 lesion, which is the primary driver for sampling in this biopsy-naive setting. This finding aligns with the EXPERT-PROTOCOL criterion, which mandates biopsy for PI-RADS 3 or higher lesions. The rising PSA trajectory from 4.2 ng/mL to 5.9 ng/mL further supports the need for tissue diagnosis. The statistical prior and the guideline criterion converged on this decision, and the retrieved evidence confirmed the high-risk imaging finding.

Variables that carried weight: age=important, dre=noted, psa=important, vol=noted, psad=important, pirads=decisive, comorbidity=noted
Sections revealed: radiology_report, psa_trend, previous_notes, laboratory_results
